| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 8, 2026 | CurifyLabs Secures $14M to Bring Personalized Medicine to More Pharmacies | Helsinki-based health technology firm CurifyLabs has closed a $14 million Series A round to grow its automated system for producing personalized medications. The round was co-led by Sandwater and HealthCap, with Tesi and existing backers in... |
| Jul 7, 2026 | CurifyLabs Raises $14 Million Series A To Power Personalized Medicine | CurifyLabs announced that it has raised $14 million in Series A funding to expand its personalized medicine platform. The round was co-led by Sandwater and HealthCap, with participation from Tesi and existing investors, including Lifeline V... |
| Jul 6, 2026 | CurifyLabs bags €12M to automate personalised medicine | Finnish health technology company CurifyLabs has raised €12 million in a Series A funding round to expand its operations in the United States and accelerate the development of its platform for personalised medicine manufacturing. The round ... |
| Jul 6, 2026 | CurifyLabs Raises $14M in Series A Funding | CurifyLabs, a Helsinki, Finland-based healthtech startup that automates the process of pharmaceutical compounding, raised $14M in Series A funding.
The round was led by Sandwater and HealthCap, with participation from Tesi, and existing inv... |
| Jun 29, 2026 | Andera Partners joins the European Life Sciences Coalition (ELSC) with the aim to support the mobilization of capital for life sciences innovation in Europe. | Andera Partners joins the European Life Sciences Coalition (ELSC), alongside Forbion, HealthCap, Novo Holdings, Omega Funds, Sofinnova Partners, Van Lanschot Kempen, VIB, BioInnovation Institute, 4BIO Capital, Cooley and Covington.
Launched... |
| Jun 17, 2026 | Great news from Swecare member Neobiomics! | Great news from Swecare member Neobiomics!
Wed, Jun 17, 2026 11:20 CET Report this content
Exciting news from Swecare member Neobiomics, which has announced a new investment led by HealthCap, one of Europe’s leading life science venture cap... |
| Jun 17, 2026 | Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat | STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase ... |
| Jun 17, 2026 | Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat | Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
Wed, Jun 17, 2026 09:00 CET Report this content
STOCKHOLM, SWEDEN – June 17, 2026. Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company f... |
| Mar 17, 2026 | /C O R R E C T I O N -- Gesynta Pharma/ | In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as ... |
| Mar 11, 2026 | First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat | STOCKHOLM, March 11, 2026 /PRNewswire/ -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for end... |
| Feb 5, 2026 | Intervacc announces change of CEO | Intervacc announces change of CEO
Thu, Feb 05, 2026 19:15 CET Report this content
The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that he will leave his role as Chief Executive Officer and Group CEO.
S... |
| Oct 28, 2025 | Hemab Therapeutics Secures $157M for Breakthrough Bleeding Disorder Therapies | Hemab Therapeutics closed a $157 million Series C funding round. The clinical-stage biotechnology firm targets severe, underserved bleeding and thrombotic disorders. This significant capital influx will accelerate two flagship programs: HMB... |
| Oct 27, 2025 | Hemab Therapeutics: $157 Million Series C Secured For Advancing Treatments For Underserved Bleeding Disorders | Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious bleeding and thrombotic disorders, announced that it has completed a $157 million Series C financing. The oversubscribed fundi... |
| Oct 27, 2025 | Hemab Therapeutics Raises $157M in Series C Financing | Hemab Therapeutics, a Cambridge, MA, and Copenhagen, Denmark-based clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, closed a $157m Series C financing... |
| Sep 18, 2025 | Capital meets care: 10 venture capital firms transforming healthcare across Europe | Venture capital remains one of the cornerstones of Europe’s innovation landscape, fuelling the growth of startups across every sector. In our last list, we spotlighted 15 VC firms focused on sustainability, underlining how investors are sha... |
| Aug 29, 2025 | Interim report January – June 2025 | Interim report January – June 2025
Fri, Aug 29, 2025 08:30 CET Report this content
The Group in summary
01/04/25 01/04/24 01/01/25 01/01/24 Full year
-30/06/25 -30/06/24 -30/06/25 -30/06/24 2024
Net sales 7 012 2 735 11 586 5 129 11 787
Ope... |
| Jun 13, 2025 | Positrigo raises CHF 7 million to commercialise its brain imaging device |
NeuroLF – Positrigo’s first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders. With ... |
| May 26, 2025 | HealthCap V distributes its holding in BONESUPPORT to its limited partners and general partner | HealthCap V distributes its holding in BONESUPPORT to its limited partners and general partner
Mon, May 26, 2025 18:00 CET Report this content
HealthCap V LP, part of the HealthCap group of venture capital funds investing globally in life s... |
| Mar 18, 2025 | Navigating Change: The Evolving Landscape of Biotechnology and Governance | In the fast-paced world of biotechnology, change is the only constant. Companies like Intervacc and Circio Holding ASA are at the forefront, navigating through financial commitments and governance adjustments. Their journeys reflect the bro... |
| Mar 18, 2025 | Oncorena receives FDA approval to initiate studies in the US | Oncorena receives FDA approval to initiate studies in the US
Tue, Mar 18, 2025 08:15 CET Report this content
Lund, Sweden, March 18, 2025 - Oncorena is pleased to announce that the FDA has approved the Company’s IND application to initiate ... |
| Mar 17, 2025 | Intervacc announces changes in the Nomination Committee | Intervacc announces changes in the Nomination Committee
Mon, Mar 17, 2025 17:40 CET Report this content
Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to the rece... |
| Mar 5, 2025 | Digital mental health startup HelloBetter secures €6M and eyes French market entry | Mental health startup HelloBetter has secured over €6 million in cash and media-for-equity, bringing its funding to €31 million.
HelloBetter is a pioneer in digital mental health research. Founded in 2015 by Prof Dr David Ebert, Dr Hanne Ho... |
| Feb 13, 2025 | Year-end report January – December 2024 | Year-end report January – December 2024
Thu, Feb 13, 2025 08:30 CET Report this content
The Group in summary
01/10/24 01/10/23 Full year Full year -31/12/24 -31/12/23 2024 2023 Net sales 4 127 1 626 11 787 8 015 Operating result -18 505 -20... |
| Sep 20, 2022 | Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies | What You Should Know:
Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondri... |
| May 25, 2022 | Annual General Meeting in Oncopeptides AB (publ) | Annual General Meeting in Oncopeptides AB (publ)
Wed, May 25, 2022 15:15 CET Report this content
STOCKHOLM — May 25, 2022 — The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stoc... |
| Mar 10, 2022 | Saying hello to better mental health! German startup unlocks €10 million for digital therapeutics | Berlin-based digital mental healthcare company HelloBetter has raised €4 million extension of its recently announced €6 million Series A funding. This brings the total investment raised in the round to €10 million. The round was led by Mass... |
| Jun 21, 2021 | Sweden’s medical history digitiser and collaboration platform Doctrin raises €13 million | Doctrin, a medtech startup hailing from Stockholm, has raised €13 million to further its efforts of providing, “patient-centric healthcare, free from barriers”. In doing so, Doctrin is now looking beyond its existing markets of Sweden, the ... |
| Apr 29, 2021 | Ysios Capital leads a €51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and Gilde | ADCENDO RAISES €51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF CANCERS.
Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company
Plans to build a pipeline o... |
| Apr 29, 2021 | Ysios Capital lidera una inversión de €51 millones en Adcendo. Acuden también Novo Seeds, RA Capital Management, HealthCap y Gilde | 29/04/2021
Nota de prensa
YSIOS CAPITAL LIDERA UNA INVERSIÓN DE €51 MILLONES EN ADCENDO.
− Adcendo (Copenhague, Dinamarca), es una compañía biotecnológica especializada en el desarrollo de fármacos inmunoconjugados para el tratamiento de... |
| Nov 19, 2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forb... |
| Jun 22, 2016 | Nordic drugmakers raise $29M to expand cancer clinical trial programs | A pair of Nordic drugmakers has raised a combined $29 million (€26 million) to advance and expand their respective cancer trials. Midphase renal cancer and melanoma player Immunicum (STO:IMMU) accounted for SEK 128 million ($15.5 million) o... |
| Apr 2, 2015 | Biotech firm Vaxin raises $8M [Startup Roundup] | WHO’S GETTING FUNDED?
Gaithersburg, Md.-based Vaxin, a biotech company focused on developing “novel vaccines,” raised $8 million, the company’s president and CEO Bill Enright told Technical.ly DC. That’s out of a projected $16 million post-... |
| INDUSTRIFONDEN JOINS GLIONOVA SEK 42 MILLION ($5.7 MILLION) FINANCING CO-LED BY HEALTHCAP AND NOVO | STOCKHOLM, December 09, 2014 – Glionova Therapeutics, an oncology-focused biopharmaceutical company today announced that Industrifonden has joined a SEK 42 million (US$ 5.7 million) Series A financing co-led by Novo Seeds and the company’s ... |
| INDUSTRIFONDEN JOINS GLIONOVA SEK 42 MILLION ($5.7 MILLION) FINANCING CO-LED BY HEALTHCAP AND NOVO TO TAKE NOVEL THERAPY FOR GLIOBLASTOMA INTO CLINIC | STOCKHOLM, December 09, 2014 – Glionova Therapeutics, an oncology-focused biopharmaceutical company today announced that Industrifonden has joined a SEK 42 million (US$ 5.7 million) Series A financing co-led by Novo Seeds and the company’s ... |
| HealthCap makes 112th investment as Swedish company Modus Therapeutics completes SEK 140 million financing led by HealthCap | Funds to be used to continue the clinical development of sevuparin for sickle cell disease
STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a ... |
| INDUSTRIFONDEN JOINS GLIONOVA SEK 42 MILLION ($5.7 MILLION) FINANCING CO-LED BY HEALTHCAP AND NOVO | Glionova news release Industrifonden eng – STOCKHOLM, December 8, 2014
– Glionova Therapeutics, an oncology-focused biopharmaceutical company today announced that Industrifonden has joined a SEK 42 million
(US$ 5.7 million) Series A finan... |
| Sweden’s medical history digitiser and collaboration platform Doctrin raises €13 million | Doctrin, a medtech startup hailing from Stockholm, has raised €13 million to further its efforts of providing, “patient-centric healthcare, free from barriers”. In doing so, Doctrin is now looking beyond its existing markets of Sweden, the ... |
| Saying hello to better mental health! German startup unlocks €10 million for digital therapeutics | Berlin-based digital mental healthcare company HelloBetter has raised €4 million extension of its recently announced €6 million Series A funding. This brings the total investment raised in the round to €10 million. The round was led by Mass... |
| Cortendo Announces HealthCap Leads $11M (NOK 73.4M) Private Placement | October 30, 2014 — Radnor, Penn., U.S. and Göteborg, Sweden — Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company focused on orphan endocrine disorders, today announced that it has entered into an agreement (“Agreement”... |
| Trimb and Avista Capital Partners Form Strategic Partnership | Trimb Healthcare AB (“Trimb”) and Avista Capital Partners (“Avista”), a leading private equity firm, today announced that Avista is partnering with the company’s founders and management, as well as its founding investor, HealthCap, to build... |
| HealthTech company Doctrin raises SEK 100 million in financing round led by Capio and HealthCap to fuel further expansion and AI development | Source: Doctrin
|
